NIKKEI 225
38,229.11 -44.99 (-0.12%) HANG SENG
18,963.68 +487.78 (+2.64%) CRUDE OIL
78.04 -0.22 (-0.28%) GOLD FUTURES
2,368.10 -6.90 (-0.29%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
49,025.90 +378.61 (+0.78%)
MediPharm Labs Corp. (MLZ.F)
| Previous close | 0.0542 |
| Open | 0.0510 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0510 - 0.0510 |
| 52-week range | 0.0303 - 0.0700 |
| Volume | |
| Avg. volume | 1,139 |
| Market cap | 21.921M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
MediPharm Labs Sets Date to Report First Quarter 2024 Financial Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its first quarter financial results for the period ended March 31, 2024, before markets open on Wednesday, May 15, 2024.
- PR Newswire
MediPharm Labs Provides Conference Call Recording Details
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.
- PR Newswire
MediPharm Labs Reports Fourth Quarter and Full Year Results
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.
